Wuxi Biologics (Cayman) ( (HK:2269) ) just unveiled an update.
Wuxi Biologics reported strong financial results for 2024, with a 9.6% increase in revenue and a 10.5% rise in net profit, despite a challenging macroeconomic environment. The company added 151 new integrated projects, reaching a total of 817, and saw significant growth in late-phase and non-COVID commercial manufacturing projects. This expansion, particularly through the ‘Win-the-Molecule’ strategy, positions Wuxi Biologics for future revenue growth and strengthens its market presence.
More about Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman) Inc. operates in the biologics industry, providing a fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform. The company focuses on biologics development and manufacturing, employing strategies like ‘Follow and Win the Molecule’ to secure projects and drive growth.
YTD Price Performance: 71.30%
Average Trading Volume: 3,786
Technical Sentiment Signal: Sell
Current Market Cap: $13.92B
For an in-depth examination of 2269 stock, go to TipRanks’ Stock Analysis page.